Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.
NCT ID: NCT03947762
Last Updated: 2021-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
54 participants
OBSERVATIONAL
2019-07-03
2021-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
NCT02651987
Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
NCT00842348
A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
NCT02288377
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
NCT03017690
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
NCT00417209
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects diagnosed of functioning or non-functioning PanNET, G1/ G2 (Ki67≤10%) unresectable locally advanced tumour or metastatic disease, who have been treated with lanreotide 120mg every 28 days for at least 3 months and a maximum of 12 months
* Subject not progressive at inclusion study visit according to investigator assessment, and using as a reference lanreotide initiation
* Subject with Eastern Cooperative Oncology Group (ECOG) ≤2
Exclusion Criteria
* Pregnant or breast-feeding women
* Subject who has received any previous therapy for PanNET (such as octreotide LAR, Molecular Targeted Therapy (MTT), Peptide receptor radionuclide therapy (PRRT), chemotherapy, etc.) except short-acting octreotide subcutaneous (SC) used for symptomatic control of functioning tumours
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IPO Coimbra
Coimbra, , Portugal
IPO Lisboa
Lisbon, , Portugal
Hospital São João
Porto, , Portugal
Hospital General de Alicante
Alicante, , Spain
Hospital Torrecardenas
Almería, , Spain
Hospital Universitario de Badajoz
Badajoz, , Spain
ICO Badalona
Badalona, , Spain
Hospital de Cruces
Barakaldo, , Spain
Hospital Universitario Vall Hebrón
Barcelona, , Spain
Hospital Santa Creu I Sant Pau
Barcelona, , Spain
Hospital Basurto
Bilbao, , Spain
Hospital Universitario de Burgos
Burgos, , Spain
Hospital Universitario Puerto Real
Cadiz, , Spain
Hospital San Pedro de Alcántara
Cáceres, , Spain
Hospital General Ciudad Real
Ciudad Real, , Spain
Hospital Universitario Reina Sofia
Córdoba, , Spain
Hospital Donostia
Donostia / San Sebastian, , Spain
Hospital Virgen de las Nieves
Granada, , Spain
Hospital Juan Ramón Jimenez
Huelva, , Spain
Hospital Can Misses
Ibiza Town, , Spain
Hospital de Jerez
Jerez de la Frontera, , Spain
ICO Bellvitge
L'Hospitalet de Llobregat, , Spain
Hospital U. de Gran Canaria Negrín
Las Palmas de Gran Canaria, , Spain
Hospital Virgen de La Victoria
Málaga, , Spain
Hospital Clínico U. Virgen de la Arrixaca
Murcia, , Spain
Hospital Morales Meseguer
Murcia, , Spain
Hospital Santa María Nai
Ourense, , Spain
Hospital Universitario Central de Asturias
Oviedo, , Spain
Hospital Son Espases
Palma de Mallorca, , Spain
Hospital de Navarra
Pamplona, , Spain
Hospital Sant Joan de Reus
Reus, , Spain
Corporació Sanitària Parc Taulí
Sabadell, , Spain
Hospital Clínico de Salamanca
Salamanca, , Spain
Hospital U. Nuestra Señora de Candelaria
Santa Cruz de Tenerife, , Spain
Hospital Marqués de Valdecillas
Santander, , Spain
Hospital Conxo
Santiago de Compostela, , Spain
Hospital General de Segovia
Segovia, , Spain
Hospital Virgen Macarena
Seville, , Spain
Hs. Virgen del Rocio
Seville, , Spain
Hospital Mutua Terrassa
Terrassa, , Spain
Hospital Virgen de la Salud Toledo
Toledo, , Spain
Hospital General de Valencia
Valencia, , Spain
Hospital Universitario y Politécnico La Fe
Valencia, , Spain
Hospital Álvaro Cunqueiro
Vigo, , Spain
Hospital Lozano Blesa
Zaragoza, , Spain
Hospital Miguel Servet
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IPS-LAN-2018-01
Identifier Type: OTHER
Identifier Source: secondary_id
A-ES-52030-383
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.